Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.
Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.
Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.
Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.
Registry search results
Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:44 UTC. Counts are registry matches, not unique peptides or a worldwide total.
Argentina · Belgium · Canada · Colombia · Czechia · Denmark · Hungary · Poland · Spain · United Kingdom · United States
Registry dates and results
Start: 2013-01-31. Completion: 2015-05-14 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Romozosumab (drug) — also listed as: AMG 785
Teriparatide (drug) — also listed as: Forteo, Forsteo
Where the study takes place — 50 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Gainesville, Georgia, United States
Explore the world’s study registries
These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.
Secondary Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder; Dialysis; Hypocalcemia; Hypoparathyroidism
Sponsor
Saint Petersburg State University, Russia
Countries with listed sites
Russia
Registry dates and results
Start: 2021-03-01. Completion: 2022-02-16 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Teriparatide (drug) — also listed as: Forsteo
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Saint-Petersburg State University Hospital Saint Petersburg, Russia Site recruitment: Not reported
Start: 2022-02-21. Completion: 2022-10-17 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
RT-102 (80 μg) (combination_product)
Forteo (drug)
RT-102 (20 μg) (combination_product)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Nucleus Network Melbourne, Australia Site recruitment: Not reported
Low Bone Mineral Density; Postmenopausal Osteoporosis
Sponsor
Amgen
Countries with listed sites
No country reported
Registry dates and results
Start: 2009-06-03. Completion: 2016-02-18 (may be estimated). Results are posted in this registry.
Products and interventions (7)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Placebo to Romosozumab (drug)
Alendronate (drug) — also listed as: Fosamax
Teriparatide (drug) — also listed as: Forsteo
Romosozumab (drug) — also listed as: AMG 785, EVENITY™
Denosumab (drug) — also listed as: Prolia®
Placebo to Denosumab (drug)
Zoledronic acid (drug) — also listed as: Aclasta
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The registry does not list facilities in this record. This does not mean the study has no sites.
Start: 2017-05-01. Completion: 2021-07-08 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Teriparatide Prefilled Syringe (drug) — also listed as: Forteo
Placebo (drug) — also listed as: Placebo prefilled syringe
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Hospital for Special Surgery New York, New York, United States Site recruitment: Not reported
Start: 2021-06-15. Completion: 2024-04-14 (may be estimated). No results posted in this registry response.
Products and interventions (0)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Where the study takes place — 10 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Hospital Parc Taulí Barcelona, Spain Site recruitment: Not reported
Hospital Universitario Igualada Barcelona, Spain Site recruitment: Not reported
Hospital 12 de Octubre Madrid, Spain Site recruitment: Not reported
Hospital de La Princesa Madrid, Spain Site recruitment: Not reported
Hospital Fundación Jimenez Diaz Madrid, Spain Site recruitment: Not reported
Hospital Infanta Leonor Madrid, Spain Site recruitment: Not reported
Instituto Palacio de Madrid Madrid, Spain Site recruitment: Not reported
Complejo Hospitalario Universitario de Orense Ourense, Spain Site recruitment: Not reported
Hospital Universitario Central de Asturias Oviedo, Spain Site recruitment: Not reported
Hospital Virgen Macarena Seville, Spain Site recruitment: Not reported
Start: 2007-02. Completion: 2008-08 (may be estimated). Results are posted in this registry.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Teriparatide (drug) — also listed as: Forteo
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University of Maryland School of Medicine Division of Endocrinology Baltimore, Maryland, United States Site recruitment: Not reported
Hip Fracture; Vertebral Fracture; Other Low-trauma Fracture
Sponsor
Oslo University Hospital
Countries with listed sites
Norway
Registry dates and results
Start: 2015-05. Completion: 2020-05 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Fracture Liaison Service (other)
Current treatment (other)
Where the study takes place — 7 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Haukeland University Hospital Bergen, Norway Site recruitment: Not reported
Drammen Hospital Drammen, Norway Site recruitment: Not reported
Molde Hospital Molde, Norway Site recruitment: Not reported
Oslo University Hospital Oslo, Norway Site recruitment: Not reported
Bærum Hospital Sandvika, Norway Site recruitment: Not reported
University Hospital of North Norway Tromsø, Norway Site recruitment: Not reported
St. Olavs University Hospital Trondheim, Norway Site recruitment: Not reported
Start: 2018-10-09. Completion: 2025-10-08 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
"Teriparatide", "Forteo® or Teribon" (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Yukio Nakamura Matsumoto, Nagano, Japan Site recruitment: Recruiting
Start: 2020-09-01. Completion: 2022-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
WJ-MSC (drug) — also listed as: teriparatide
Teriparatide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
CHA University, CHA Bundang Medical Center Seongnam-si, Gyeonggi-do, South Korea Site recruitment: Not reported
Norfolk and Norwich University Hospitals NHS Foundation Trust
Countries with listed sites
United Kingdom
Registry dates and results
Start: 2021-05-24. Completion: 2021-07-09 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Teriparatide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Norfolk and Norwich University Hospitals Foundation Trust Norwich, Norfolk, United Kingdom Site recruitment: Not reported
Post Graduate Institute of Medical Education and Research, Chandigarh
Countries with listed sites
India
Registry dates and results
Start: 2014-01. Completion: 2018-12 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Teriparatide (drug) — also listed as: parathyroid hormone, recombinant human parathyroid hormone
Placebo (other)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Deptt of Endocrinology Chandigarh, India Site recruitment: Not reported
PGIMER Chandigarh, India Site recruitment: Not reported
Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment
Sponsor
Assistance Publique - Hôpitaux de Paris
Countries with listed sites
France
Registry dates and results
Start: 2017-06-06. Completion: 2020-05-28 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Teriparatide (drug) — also listed as: FORSTEO
Thiazide (drug) — also listed as: ESIDREX
Potassium sparing diuretic (drug) — also listed as: MODAMIDE
Alfacalcidol (drug) — also listed as: UN-ALFA
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
AP-HP Hopital Europeen Georges Pompidou Paris, France Site recruitment: Not reported
Start: 2019-06-30. Completion: 2021-05-11 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
EBP05 (drug) — also listed as: hPTH(1-34), Teriparatide
Placebo of EBP05 (drug) — also listed as: Placebo
Where the study takes place — 4 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Hadassah Medical Center, Mt. Scopus Hospital Jerusalem, Israel Site recruitment: Not reported
Rabin Medical Center, Beilinson Campus Petah Tikva, Israel Site recruitment: Not reported
Sheba Medical Center Ramat Gan, Israel Site recruitment: Not reported
Tel-Aviv Sourasky Medical Center Tel Aviv, Israel Site recruitment: Not reported
Start: 2012-11. Completion: 2021-06-01 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Zoledronic acid (drug) — also listed as: zolendronate, Aclasta
Teriparatide (drug) — also listed as: PTH, Forsteo
No active treatment (other)
Where the study takes place — 3 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Osteoporosis clinic; department of endocrinology and metabolism Aarhus, Aarhus C, Denmark Site recruitment: Not reported
Department of endocrinology Hvidovre, Denmark Site recruitment: Not reported
Department of Endocrinology M Odense, Denmark Site recruitment: Not reported
Start: 2011-08. Completion: 2016-12 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
teriparatide (biological) — also listed as: Forteo, recombinant human parathyroid hormone (1-34)
Placebo (biological)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
UCSF Spine Center San Francisco, California, United States Site recruitment: Not reported
Start: 2020-08-19. Completion: 2020-11-11 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
SAL001 (biological)
FORSTEO (biological)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China Site recruitment: Not reported
Start: 2014-08. Completion: 2020-02 (may be estimated). Results are posted in this registry.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
denosumab (drug) — also listed as: Prolia
teriparatide (drug) — also listed as: Forteo
Zoledronic acid (drug) — also listed as: Reclast
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Massachusetts General Hospital Boston, Massachusetts, United States Site recruitment: Not reported
Start: 2019-06-01. Completion: 2020-11-10 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Teriparatide (drug) — also listed as: rhPTH 1-34
Denosumab (drug) — also listed as: RANKL inhibitor
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
424 General Military Hospital Thessaloniki, Northern Greece, Greece Site recruitment: Not reported
Start: 2014-10. Completion: 2018-12 (may be estimated). No results posted in this registry response.
Products and interventions (0)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
UZ Leuven Leuven, Belgium Site recruitment: Not reported
GEOMAR-Helmholtz Centre for Ocean Research Kiel, Germany Site recruitment: Not reported
Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.